PolyPeptide Announces Positive Outcomes at 2024 Annual General Meeting

PolyPeptide Group AG, a leading CDMO specializing in peptide- and oligonucleotide-based APIs, held its 2024 Annual General Meeting on April 10, in Baar, with significant shareholder participation. The meeting, which was the company's third annual event, saw a strong showing with 75.79% of share voting rights represented. Peter Wilden, the Chair of the Board, presided over the meeting at Chollerhalle, Zug.

All proposals set forth by the Board of Directors received overwhelming support from the shareholders. This included the reappointment of six Board members until the next meeting in 2025, with Peter Wilden continuing as Chair. Key resolutions spanned the removal of certain compensation limits for Board consulting, the re-election of Statutory Auditors and the Independent Proxy, and the approval of compensation caps for the Board and Executive Committee for upcoming periods. Additionally, shareholders ratified the financial statements for the fiscal year 2023 and discharged board and committee members from liability for the same period.

The outcome reaffirms shareholder confidence in PolyPeptide’s governance and strategic direction. Detailed minutes of the AGM 2024 will be accessible on the company's website within 15 days, and the next annual meeting is scheduled for April 9, 2025.